With $185 million in series A funding and an army of experienced leaders in its ranks, Braveheart Bio is setting off to joust ...

As momentum for Biogen’s newer drugs for neurological disorders builds at a slow and steady pace, it appears that the company ...

Alnylam and Neurocrine shares tumbled despite upbeat sales reports. Elsewhere, Biogen is dealing with what one analyst called ...

Biogen beat Wall Street estimates for third-quarter profit, helped by better-than-expected sales of some of its multiple ...

Biogen (BIIB) shares have shown some movement recently, and investors may be taking a closer look at what is driving performance. Over the past month, the stock has dipped around 3%. See our latest ...

In a report released today, Sumant Kulkarni from Canaccord Genuity reiterated a Buy rating on Biogen, with a price target of $220.00. The company’s shares closed yesterday at $149.61. Take advantage ...

Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results this Thursday before market open. Here’s what to ...

US biotech Biogen (Nasdaq: BIIB) reported third-quarter 2025 revenue of $2.5 billion, up 3%, with GAAP diluted EPS of $3.17, ...

AI-generated summary reviewed by our newsroom. Read our AI Policy. Biogen plans to beef up its Research Triangle Park operations with $2 billion in new local spending, the company announced Monday.

Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

Portfolio Receipts growth of 11% to $814 million; Royalty Receipts growth of 11% Net cash provided by operating activities of $703 million Raised ...

Biogen employees work inside a lab used to produce cell cultures in 2014 at the firm’s Research Triangle Park facilities. N&O file photo Biogen commits $2 billion to expand RTP campuses in Wake and ...